| Bioactivity | Verdiperstat (AZD3241) is a selective, irreversible and orally active myeloperoxidase (MPO) inhibitor, with an IC50 of 630 nM, and can be used in the research of neurodegenerative brain disorders. | ||||||||||||
| Target | IC50: 630 nM (Myeloperoxidase) | ||||||||||||
| Invitro | Verdiperstat (AZD3241) is a myeloperoxidase (MPO) inhibitor, with an IC50 of 630 nM, and is used in the research of neurodegenerative brain disorders[1]. Verdiperstat (AZD3241) selectively and irreversibly inhibits myeloperoxidase, and may involves reduction of oxidative stress leading to reduction of sustained neuroinflammation[2]. | ||||||||||||
| Name | Verdiperstat | ||||||||||||
| CAS | 890655-80-8 | ||||||||||||
| Formula | C11H15N3O2S | ||||||||||||
| Molar Mass | 253.32 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Johnström P, et al. Development of rapid multistep carbon-11 radiosynthesis of the myeloperoxidase inhibitor AZD3241 to assess brain exposure by PET microdosing. Nucl Med Biol. 2015 Jun;42(6):555-60. [2]. Jucaite A, et al. Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease. Brain. 2015 Sep;138(Pt 9):2687-700. |